香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681) 自願公告 訂立戰略合作協議以拓展日本及東南亞市場及 搭建老年人AI數字健康一體化平台 本公告由腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司已於近日與東京生活館株式會社 (Tokyo Lifestyle Co., Ltd)（「Tokyo Lifestyle」或「合作方」）訂立戰略合作協議（「本 協議」）。雙方將圍繞認知障礙數字療法與功能健康品的深度融合，在日本及東南 亞等地區共同探索「線上認知能力檢測及訓練康復+線下功能健康品有機結合」的 一體化平台模式，致力於為老年人搭建AI數字健康一體化平台。 一、合作方介紹 東京生活館 ...

Core Insights - Dexcom's G7 product significantly reduces A1C levels and improves weight management in non-insulin-dependent type 2 diabetes patients, indicating a shift towards a larger market segment [2][8] - The company is transitioning from a focus on insulin-dependent patients to a broader base of type 2 diabetes patients who do not use insulin, which could redefine market potential [5][8] Group 1: Company Overview - Dexcom, established in 1999, is a pioneer in the commercialization of Continuous Glucose Monitoring (CGM) systems and remains a key player in the high-end CGM market [3] - The latest G7 product features smaller size, longer wear time (15 days), and enhanced data connectivity and algorithm capabilities, marking a shift from professional devices to consumer-grade wearables [6] Group 2: Market Dynamics - The CGM market is evolving from hospital-based monitoring to long-term management outside clinical settings, emphasizing data-driven diabetes management [6][10] - The focus is shifting from merely providing data to actively changing patient behavior and treatment outcomes, with tools like "Smart Basal" entering the algorithm-assisted treatment phase [10] Group 3: Implications for the Chinese Market - The growth potential in China lies outside hospitals, focusing on broader chronic disease management rather than just insulin-dependent patients [14] - Future competition will center on "data + services," moving beyond just sensor sales to include comprehensive management solutions [15][16] - Payment systems will be a critical factor in the adoption of CGM among non-insulin users, with successful expansion relying on a combination of payment frameworks and clinical evidence [19][20] Group 4: Future Growth Trajectory - The CGM industry is entering a "second growth curve," transitioning from replacing fingerstick blood tests to becoming a core tool in chronic disease management [21] - This next phase will be driven by expanding the patient population and realizing the value of data [22]

Group 1 - The article highlights the collaboration between Northern Light Venture Capital and Chuangyebang to celebrate the growth of entrepreneurial companies, specifically XSKY and BrainCo, discussing themes of ideals, growth, and values [3][4] - BrainCo, established in 2019, has emerged as a leading digital therapy company, successfully listing on the Hong Kong Stock Exchange in January 2025, becoming the first digital therapy stock in China [10] - The narrative emphasizes the challenges faced by BrainCo, including a period of financial struggle where the team of over thirty had to persevere through difficult times while maintaining their vision [5][6] Group 2 - The article poses questions about the journey of BrainCo, exploring whether their success was due to luck or persistence, and how they navigated through their darkest moments [8] - It discusses the nature of digital therapy, which aims to address serious conditions like Alzheimer's and depression, questioning whether it represents genuine innovation or a potential bubble [8] - The story of BrainCo is framed as an inspiring example for entrepreneurs and those interested in the future of healthcare and technology, illustrating how a company can find hope in despair [8]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has signed a strategic cooperation agreement with the Macau Kiang Wu Hospital to establish a comprehensive brain health service model in the Macau region, focusing on digital screening, assessment, training, and health management for cognitive disorders [1] Group 1 - The company's stock rose by 4.32%, reaching HKD 4.83, with a trading volume of HKD 48.71 million [1] - The partnership with the influential private hospital in Macau is seen as a benchmark for the company, paving the way for future expansion in the Greater Bay Area [1] - This collaboration enhances the company's ecosystem alliance with authoritative medical institutions, complementing its recent national-level project cooperation with the National Rehabilitation Aids Research Center [1]

Core Viewpoint - The company has signed a strategic cooperation agreement with Macau's Kiang Wu Hospital to establish a comprehensive brain health service model, focusing on cognitive impairment screening, assessment, training, and health management in the Macau region [1][2]. Group 1: Cooperation Details - The collaboration will involve the establishment of a "Brain Health Center" within Kiang Wu Hospital, providing a one-stop service from early screening to digital cognitive training and follow-up management [1]. - The services will cater to all age groups, including individuals aged 60 and above at risk of cognitive impairment and children aged 3 to 18 with neurodevelopmental disorders, offering both in-hospital and home-based digital therapy [1]. - Data security and compliance will be ensured by localizing data storage and processing in accordance with Macau's laws, preventing data from being transmitted outside the region [1]. Group 2: Strategic Significance - This partnership is expected to set a benchmark and expand the company's market presence in the Greater Bay Area, serving as a model for future projects in other cities [2]. - The collaboration aims to accumulate high-quality real-world data for further scientific research on cognitive function diseases, enhancing diagnostic services and product development [2]. - The initiative addresses the urgent health needs in Macau, potentially reducing the incidence of severe dementia and providing sustainable service revenue for the company [2]. Group 3: Academic and Research Collaboration - The partnership will enhance the company's ecosystem by integrating resources from mainland and Macau experts, promoting the construction of a brain health medical center and related clinical research [2][3]. - This collaboration aligns with the company's recent national-level project with the Ministry of Civil Affairs, fostering the standardization and large-scale application of cognitive digital therapies [3].

Core Viewpoint - The company has established a strategic partnership with Macau's Kiang Wu Hospital to develop a comprehensive brain health service model, focusing on cognitive impairment screening, assessment, training, and management in the Macau region [1][2]. Group 1: Partnership Details - The collaboration will involve the establishment of a "Brain Health Center" at Kiang Wu Hospital, providing a one-stop service from early screening to digital cognitive training and follow-up [2]. - The services will cater to all age groups, including individuals aged 60 and above at risk of cognitive impairment and children aged 3 to 18 with neurodevelopmental disorders [2]. - Data security and compliance will be ensured by localizing data storage and adhering to Macau's legal regulations [2]. Group 2: Strategic Significance - The partnership sets a benchmark for the company, facilitating market expansion in the Greater Bay Area by establishing a replicable model for digital therapy in Hong Kong and Macau [3]. - The collaboration will accumulate high-quality real-world data for further scientific research on cognitive function diseases, enhancing the company's technological advantage in providing diagnostic services [3]. - The initiative addresses the urgent health needs in Macau, potentially reducing the incidence of severe dementia and creating sustainable service revenue for the company [3]. - The partnership strengthens the company's academic and research alliances, complementing recent collaborations with national research centers to promote standardized and scalable applications of cognitive digital therapy [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 與澳門鏡湖醫院簽署腦健康數字AI技術服務合作協議 本公告乃腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在知會本公司股東及潛在投資者本集團於港澳地區之最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司－腦動極光醫學 科技數智（澳門）有限公司（「腦動極光澳門」），已於近期與澳門鏡湖醫院（「鏡湖 醫院」）正式簽署《腦健康數字AI技術服務合作協議》（「該協議」）。雙方將圍繞認 知障礙的數字篩查、評估、訓練及全程健康管理，在澳門地區建立長期戰略合作 關係，共同構建覆蓋「醫院 － 社區 － 家居」的全鏈條腦健康服務新模式（「本次合 作」）。 一、合作背景 董事會認為，本次合作對本集團 ...

Core Viewpoint - The company Brainstorm Cell Therapeutics (06681) has seen a stock increase of over 13% following the announcement of a strategic partnership with Silk Road Technology Co., Ltd. to expand its digital therapy products in Malaysia and Southeast Asia [1] Group 1 - The strategic cooperation agreement aims to localize, promote, and transform research related to cognitive impairment digital therapy products in the Malaysian and Southeast Asian markets [1] - The board believes this partnership marks the company's official entry into the Malaysian market, further expanding its Southeast Asian business network [1] - The collaboration is expected to leverage the company's validated digital therapy experience and technology from the Chinese market to enhance its brand influence and business coverage internationally [1]

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology to localize and promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry in the region [1][2]. Group 1: Market Context - Malaysia is facing challenges due to rapid population aging and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a psychological counseling ratio of 1:52,000, far below the international standard of 1:500, indicating a substantial market gap [1]. Group 2: Company Background - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first regulatory-approved digital therapy for cognitive impairment, included in the reimbursement catalog of provincial medical insurance in 30 provinces in China [1]. Group 3: Partnership Details - The partnership includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Technology assisting in local approvals and logistics while the company provides technical and research support [3]. - The collaboration will also involve applying for national innovation pilot projects, conducting clinical trials in selected hospitals, and jointly expanding market reach in Malaysia and other Southeast Asian countries like Indonesia, Thailand, and Vietnam [3]. Group 4: Strategic Benefits - This collaboration is expected to create long-term growth opportunities for the company and sustainable value for shareholders by expanding its international presence and leveraging local resources for efficient market entry [4]. - The partnership enhances the company's brand authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions and broadening its market in digital health management [4].

BrainAurora Medical Technology Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6681） 自願公告 訂立戰略合作協議以拓展馬來西亞市場及深化國際化布局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發布的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣布，本公司與絲路之舟科技有限公司（「絲路之 舟」）訂立戰略合作協議（「協議」），雙方將在馬來西亞及東南亞區域圍繞認知障礙 數字療法產品的本土化落地、市場推廣與科研轉化等領域開展深度戰略合作，共 同推動數字健康產業發展。 合作背景與內容 馬來西亞為東南亞重要經濟體之一，正面臨快速人口老化及精神健康需求攀升 的挑戰。根據馬來西亞統計局數據，2023年該國60歲以上人口達380萬。與此同 時，青少年心理健康問題亦日益突出。馬來西亞政府雖已推動多項精神健康政 策，然診療資源仍顯稀 ...